QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Read Quantify´s publication assessing recent changes to adult national immunization programs for pneumococcal vaccination
In December 2023, Quantify’s Stuti Arya, Nicholas Norton and Puneet Kaushik published a study assessing recent changes to adult national immunization programs for pneumococcal vaccination and attempting to determine how those changes impacted coverage in European Adults. The review revealed evidence of a convergence towards immunization programs involving sequential vaccination with a higher-valency conjugate vaccine (PCV) followed by the polysaccharide vaccine (PPV23), with a common aim of reducing economic […]
New publication on the burden of AOM by Quantify´s Helena Skröder and Nicholas Norton
In April 2024, Quantify’s Helena Skröder and Nicholas Norton published a study quantifying the burden of acute otitis media (AOM) caused by pneumoniae, after widespread use of PCVs. The review found evidence of reductions in hospitalizations and antibiotic resistance following extensive use of PCVs, implying a reduction in economic burden, though further economic evidence is needed to confirm. However, there […]
Welcome Simon Dawson!
Today, we are excited to warmly welcome Simon Dawson to the Quantify Research team as Director of Strategic Value Communication and Access!
Simon brings a unique combination of commercial, sales and market access experience from a range of industry and consulting roles spanning Nordic, European and Global markets.
Simon joins us from Alnylam Pharmaceuticals where he served as Nordic Commercial Lead. During his tenure, his strategic thinking and tailored product value […]
Ispor days
The Quantify team enjoyed reconnecting with colleagues, meeting new faces, presenting our research, and drawing inspiration from the scientific program.
We’re already excited for ISPOR EU in Barcelona! If we didn’t get a chance to meet or if you’d like to discuss potential collaborations, please don’t hesitate to reach out at info@quantifyresearch.com.
What stood out for you at ISPOR this year? Share with us in […]